TARS (Tarsus Pharmaceuticals) Current Accrued Expense: $79.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TARS Tarsus Pharmaceuticals Inc TARS
46 GF Score
Price $61.11
GF Value $210.73
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Tarsus Pharmaceuticals Current Accrued Expense?

Tarsus Pharmaceuticals TARS -0.26% 46 Current Accrued Expense is $79.0 Mil as of Mar. 2026. GuruFocus rates TARS with a GF Score™ of 46/100 and a GF Value™ of $210.73 (Possible Value Trap). The stock has 2 warning signs investors should review.

Tarsus Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2026 was $79.0 Mil.

Tarsus Pharmaceuticals's quarterly Current Accrued Expense increased from Sep. 2025 ($69.9 Mil) to Dec. 2025 ($86.2 Mil) but then declined from Dec. 2025 ($86.2 Mil) to Mar. 2026 ($79.0 Mil).

Tarsus Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 ($18.1 Mil) to Dec. 2024 ($48.9 Mil) and increased from Dec. 2024 ($48.9 Mil) to Dec. 2025 ($86.2 Mil).

Tarsus Pharmaceuticals Current Accrued Expense Related Terms

Tarsus Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Tarsus Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsus Pharmaceuticals Current Accrued Expense Chart

Tarsus Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 7.21 9.21 18.11 48.95 86.22

Tarsus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.63 56.73 69.90 86.22 79.05
TARS
46GF Score
Tarsus Pharmaceuticals Inc TARS
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tarsus Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $79.0 Mil mean?
Tarsus Pharmaceuticals (TARS) has a Current Accrued Expense of $79.0 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Tarsus Pharmaceuticals and its competitors.
Is Tarsus Pharmaceuticals' Current Accrued Expense too high?
Tarsus Pharmaceuticals' current Current Accrued Expense is $79.0 Mil. Overall, Tarsus Pharmaceuticals has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Current Accrued Expense compare to VERA and BEAM?
Tarsus Pharmaceuticals' Current Accrued Expense of $79.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Tarsus Pharmaceuticals and its competitors. Tarsus Pharmaceuticals's current Current Accrued Expense is $79.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Possible Value Trap. The stock's GF Value™ is $210.73, compared to a current price of $61.11 — trading 71% below its estimated fair value. The current Current Accrued Expense is $79.0 Mil. Tarsus Pharmaceuticals' overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Current Accrued Expense is $79.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued. The current stock price of $61.11 is trading 71% below its estimated GF Value™ of $210.73. GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TARS:

  • Current Accrued Expense: $79.0 Mil
  • GF Value™: $210.73 vs. price of $61.11 (71% below fair value)
  • GF Score™: 46/100 with 2 warning signs

No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsus Pharmaceuticals Business Description

Address 15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
46GF Score

Get the complete analysis for TARS

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$61.11
Price
$210.73
GF Value